Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.

BACKGROUND A multinational trial (APRICOT) showed that peginterferon alfa-2a (40kDa) plus ribavirin is efficacious for treatment of HIV-HCV co-infection. The cost-effectiveness of treating these patients with peginterferon alfa-2a/ribavirin has yet to be explored from a US societal perspective. OBJECTIVE To predict the cost-effectiveness of peginterferon alfa-2a/ribavirin with interferon/ribavirin (IFN/RBV) or no treatment in HIV-HCV co-infected patients. STUDY DESIGN A Markov model was constructed with liver progression estimates based on published literature. Sustained virological response and baseline characteristics of the reference case were based on APRICOT. Quality of life and costs in 2004 US dollars (US$) were based on literature estimates and discounted at 3%. RESULTS Peginterferon alfa-2a/ribavirin compared with IFN/RBV or no treatment is predicted to increase quality-adjusted life-years (QALYs) by 0.73 and 0.94 years, respectively, in HCV-genotype-1 patients. The incremental cost-effectiveness ratio of peginterferon alfa-2a/ribavirin compared with IFN/RBV and no treatment for all patients is respectively US$ 2,082 and 5,187/QALY gained. CONCLUSIONS Anti-HCV treatment is predicted to decrease the risk of cirrhosis and increase quality-adjusted survival of HIV-HCV co-infected patients compared with IFN/RBV and no treatment. Peginterferon alfa-2a/ribavirin's cost per QALY gained relative to these options falls within the cost-effectiveness level of many health technologies commonly adopted in the US.

[1]  Joshua A. Salomon,et al.  Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. , 2003 .

[2]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[3]  Murray Krahn,et al.  Health-state utilities and quality of life in hepatitis C patients. , 2003 .

[4]  J. Montaner,et al.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. , 2004, The New England journal of medicine.

[5]  J. Singh.  International society for pharmacoeconomics and outcomes research , 2006 .

[6]  S. Hammer,et al.  Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. , 1998, The Journal of infectious diseases.

[7]  J B Wong,et al.  Estimates of the Cost-Effectiveness of a Single Course of Interferon-2b in Patients with Histologically Mild Chronic Hepatitis C , 1997, Annals of Internal Medicine.

[8]  Z. Younossi,et al.  Cost effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis C , 1999, Hepatology.

[9]  W. Klaskala,et al.  Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. , 2004, The American journal of gastroenterology.

[10]  J. Brooks,et al.  An Outbreak of Vibrio cholerae O1 infections on Ebeye Island, Republic of the Marshall Islands, associated with use of an adequately chlorinated water source. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  M. Weinstein,et al.  Medicare and cost-effectiveness analysis. , 2005, The New England journal of medicine.

[12]  David R. Holtgrave,et al.  How HIV Treatment Advances Affect the Cost—Effectiveness of Prevention , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.

[13]  A. Moorman,et al.  Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  G Realdi,et al.  Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). , 1997, Journal of hepatology.

[15]  W. Powderly.  Antiretroviral therapy in patients with hepatitis and HIV: weighing risks and benefits. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  David O. Meltzer,et al.  Accounting for future costs in medical cost-effectiveness analysis. , 1997 .

[17]  D Meltzer,et al.  Addressing uncertainty in medical cost-effectiveness analysis implications of expected utility maximization for methods to perform sensitivity analysis and the use of cost-effectiveness analysis to set priorities for medical research. , 2001, Journal of health economics.

[18]  J. Rockstroh,et al.  HIV and hepatitis C virus co-infection. , 2004, The Lancet. Infectious diseases.

[19]  A Muñoz,et al.  Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.

[20]  K. Reddy,et al.  Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. , 2004, Gastroenterology.

[21]  Peter A Ubel,et al.  What is the price of life and why doesn't it increase at the rate of inflation? , 2003, Archives of internal medicine.

[22]  Amalio Telenti,et al.  Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population , 2003, The Lancet.

[23]  Terry Therneau,et al.  Cost-Effectiveness of 6 and 12 Months of Interferon- Therapy for Chronic Hepatitis C , 1997, Annals of Internal Medicine.

[24]  P. Volberding,et al.  Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. , 2004, The New England journal of medicine.

[25]  F. Carrat,et al.  Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. , 2004, JAMA.

[26]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[27]  Milton C Weinstein,et al.  Empirically calibrated model of hepatitis C virus infection in the United States. , 2002, American journal of epidemiology.

[28]  M. Sulkowski,et al.  Hepatitis C in the HIV-infected patient. , 2003, Clinics in liver disease.

[29]  T. Tsuji,et al.  Natural course of chronic hepatitis C. , 1993, The American journal of gastroenterology.

[30]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[31]  R. Willke,et al.  Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[32]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[33]  A. Alberti,et al.  Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. , 1992 .

[34]  T. Heeren,et al.  Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  A. Garber.  Cost-effectiveness and evidence evaluation as criteria for coverage policy. , 2004, Health affairs.

[36]  D. Snydman,et al.  Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  L. Kalish,et al.  Highly Active Antiretroviral Therapy Decreases Mortality and Morbidity in Patients with Advanced HIV Disease , 2001, Annals of Internal Medicine.

[38]  A. Garber,et al.  Economic foundations of cost-effectiveness analysis. , 1997, Journal of health economics.

[39]  J. Bartlett,et al.  Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. , 2004, Clinical Infectious Diseases.

[40]  J R Beck,et al.  Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[41]  S S Lee,et al.  Cost-Effectiveness of Combination Peginterferon α-2a and Ribavirin Compared With Interferon α-2b and Ribavirin in Patients With Chronic Hepatitis C , 2004, American Journal of Gastroenterology.

[42]  R. D. de Man,et al.  Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. , 1992, Gastroenterology.

[43]  W. Kim,et al.  Cost‐effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C , 2000, Hepatology.

[44]  J. Berlin,et al.  The association between hepatitis C infection and survival after orthotopic liver transplantation. , 2002, Gastroenterology.

[45]  K. Freedberg,et al.  Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. , 2002, Archives of internal medicine.

[46]  M. Weinstein,et al.  Theoretical issues in cost-effectiveness analysis. , 1997, Journal of health economics.